The pathophysiology of acute myocardial infarction is multifaceted, involving numerous biological processes. The crosstalk between cuproptosis and remodeling biomarkers may be implicated in the pathogenesis of AMI. Combining cuproptosis, LIPCAR, and α-SMA cardiac recovery analysis may enable more precise identification of diagnostic biomarkers that help for future improvement of treatment and prognosis
No linked publications found in PubMed
Inclusion Criteria: * All patients will be subjected to full history taking, meticulous general examination, and local cardiac examination * Age ≥ 18 years * AMI diagnosis : clinical, laboratory (troponins level), ECG and coronary angiography indicated occlusion or (≥50% stenosis of any coronary artery or its major branches) Exclusion Criteria: * Patients with aortic coarctation, * Coronary artery bypass grafting surgery, * Coronary intervention, * Congestive heart failure, * Rheumatic heart disease, * Presence of coronary myocardial bridges, * Organic cardiac disease such as combined heart valve disease, * Congenital heart defects, * Any inflammatory diseases like myocarditis or pericarditis, traumatic cardiac injury or other primary heart diseases, * Dilated cardiomyopathy, * Hypertrophic cardiomyopathy, * Patients complicated with malignant arrhythmias. * Patients with severe haematological disease, * Infection as tuberculosis, * Pulmonary embolism, * Organ failures or serious lesions (such as brain, lung, liver and kidney), * Severe autoimmune diseases as arthritis and inflammatory bowel disease, * Tumours, * Allergic diseases, * Connective tissue diseases, * Trauma, * And pregnant women or patients with mental disorders such as depression who are unable to cooperate with the study.